Imaging as a strategy for premortem diagnosis and staging of tauopathies.
Alzheimer's disease is diagnosed by postmortem detection of pathological lesions that accumulate in specific brain regions. Although the presence of both beta-amyloid plaques and tau-bearing neurofibrillary lesions defines Alzheimer's disease, the distribution of neurofibrillary lesions alone correlates strongly with neurodegeneration and cognitive decline. A whole-brain imaging test capable of detecting these lesions in premortem cases could have great potential for staging and differentially diagnosing Alzheimer's disease. Here we discuss the challenges in developing a whole-brain imaging approach for detection of this intracellular target.
Kim
S
S
Center for Molecular Neurobiology, Department of Molecular and Cellular Biochemistry, The Ohio State University College of Medicine, Columbus, USA.
Jensen
J R
JR
Cisek
K
K
Funk
K E
KE
Naphade
S
S
Schafer
K
K
Kuret
J
J
D000544:Alzheimer Disease / Q000175:diagnosis*; D016229:Amyloid beta-Peptides / Q000032:analysis / Q000737:chemistry / Q000378:metabolism; D001667:Binding, Competitive / Q000502:physiology; D015415:Biomarkers / Q000032:analysis; D001921:Brain / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D004396:Coloring Agents / Q000737:chemistry / Q000378:metabolism; D003952:Diagnostic Imaging / Q000379:methods* / Q000639:trends; D006801:Humans; D016874:Neurofibrillary Tangles / Q000378:metabolism / Q000473:pathology*; D011485:Protein Binding / Q000502:physiology; D024801:Tauopathies / Q000175:diagnosis*; D016875:tau Proteins / Q000032:analysis / Q000737:chemistry / Q000378:metabolism
D016229:Amyloid beta-Peptides; D015415:Biomarkers; D004396:Coloring Agents; D016875:tau Proteins